PharmaCyte Biotech Inc (PMCB)

[frosr6]

Let's post the whole story shall we?
Let's also pay attention to Semma as it's the only practical choice.

Emerging PC projects include projects which may begin human trials in the next two years. The projects listed below have received a significant amount of media coverage and represent the next-in-line PC projects. However, because none of these projects are currently testing in humans, they are likely more than [color=red] 15 years [/color away from FDA approval.

CELL TRANSPLANT WITH AUTOIMMUNE PROTECTION

Pharmacyte Biotech has begun testing its Cell-in-a-Box microencapsulation technology. Its insulin-producing Melligen cells, derived from liver cells, are being tested in mice. There is no current timeline for moving into clinical trials.

Orgenisis has developed a process to convert a patient’s liver cells into insulin-producing cells. Two clinical trials are scheduled to be performed in Germany and Belgium starting in 2017.

The DRI transplanted islet cells into the omentum in one human patient in an ongoing proof of concept phase I/II study.

Sernova is developing an encapsulation “pouch” the size of a credit card and containing donor islets. The company terminated a Phase I/II trial earlier this year.

Semma Therapeutics has commercialized Doug Melton’s work using stem cells to create beta cells. If successful, this work could be a key component of a Practical Cure. The project remains more than 24 months from starting human trials.